ReviewHNO2025
[Current aspects of nanoparticle-based therapy in head and neck cancer].
Review in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid expansion and application of nanoparticles in medicine has meanwhile contributed to a large number of experimental and clinical studies, especially in cancer research. Numerous different fields within nanomedicine have now become established more clearly. These are based on the one hand on the properties of different types of nanoparticles (chemical, physical, and biological) and on the other hand on the possible specific applications such as drug carrier, radioenhancer, in vivo monitoring of drug distribution within the tumor, or tumor-specific immune-modulating effects. Nanoparticles can also be functionalized by multiple properties potentiating their intrinsic antitumoral effects, such as coupling of antibodies to address target tissue or coupling to chemotherapeutic agents. In this work, an up-to-date overview of the developments and applications related to nanoparticles in head and neck cancer is given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.